Onset: 30–90 min post-dose (oral, with fat). Peak: 2–3 hr. Duration: 4–7 hr per dose, but effects are cumulative across 1–2 weeks — first-dose response is usually mild; full subjective profile emerges by day 5–7 of consistent dosing.

Characteristic phenomenology (compiled from anecdote + clinical descriptors):

• Verbal fluency lift — most-reported single effect. "Connecting concepts faster," easier presentation/explanation, smoother retrieval of less-frequently-used vocabulary. This is the classical "pramiracetam signature."
• Memory recall improvement — both working memory (holding more in mind during a task) and longer-term recall (names, prior conversations).
• Mental clarity / mild stim-like edge — but not stimulant pharmacology. No DA/NE release, no caffeine-like jitter. Subjective energy is more "wakefulness without effort" than "amped up."
• Mild emotion blunting / "emotional objectivity" — frequently reported, sometimes welcomed (less reactivity in stressful conversations), sometimes disliked (flat affect). Not clinically depressive.
• Frontal headache without choline cofactor — near-universal at higher doses. Reliable signal of inadequate ACh substrate. Resolves within minutes-to-hours of taking citicoline / alpha-GPC.
• Sensory enhancement reports (subset of users) — sharper visual acuity, clearer auditory detail. Less consistent than verbal/memory effects.
• Failure to respond (~20–30%) — a real and reliable failure mode. If 4 weeks of consistent dosing at 600 mg BID with adequate choline produces no subjective shift, pramiracetam is unlikely to be a high-yield compound for that individual.

Compared to piracetam: much stronger per-mg, faster subjective onset, more pronounced verbal/memory effects, larger choline requirement. Compared to aniracetam: less anxiolytic/mood-modulating, more cognitive/memory-focused, less smooth-and-creative-feeling, more "sharp focus" feeling. Compared to oxiracetam: comparable potency, similar "logical/numerical" phenomenology, oxiracetam is reportedly slightly more "energetic," pramiracetam slightly more "memory." Compared to phenylpiracetam: much less stim-like, no DA modulation, no rapid tolerance — phenylpiracetam is acute-stim, pramiracetam is sustained-cognitive. Compared to modafinil: entirely different. Modafinil is wakefulness/drive; pramiracetam is memory/verbal/recall. Stack-compatible, no overlap.

• Tolerance buildup: minimal-to-mild. Mechanism is synthesis-upregulation of HACU (not receptor agonism), so classical post-synaptic downregulation is not expected. Anecdotal reports describe mild cumulative tolerance over weeks-to-months of daily use — typically expressed as "the edge fades, but the baseline benefit holds." 1–2 week washout reportedly resets subjective sensitivity to baseline.
• Cross-tolerance with other racetams: Yes — partial. Stacking piracetam + pramiracetam doesn't fully linearly add; both work through overlapping cholinergic mechanisms. Phenylpiracetam shows the fastest tolerance and should not be stacked daily with pramiracetam.
• Recommended cycle for Dylan: PRN-only, not daily. 2–3 doses/week on high-load days, with longer breaks naturally falling on training/recovery days. If escalating to daily, run 5 days on / 2 days off and reassess after 4 weeks. Bloodwork-relevant safety unknown past 18 months continuous (longest published trial duration).
• Reset protocol if needed: 2-week complete washout. Subjective effect typically returns to baseline freshness. No withdrawal phenomenon documented.

Synergistic with

• citicoline (Dylan's V4 daily 500 mg): MANDATORY cofactor. Citicoline donates choline + cytidine (→ uridine → membrane phospholipids). The single best pairing — covers HACU substrate demand and provides membrane-side support. Already in Dylan's V4 stack — direct fit.
• alpha-gpc: Alternative choline cofactor; faster ACh substrate provision (more direct than citicoline). Many users prefer alpha-GPC with pramiracetam specifically because of the higher acute choline yield. Either citicoline OR alpha-GPC works; alpha-GPC has a small subjective edge for some.
• modafinil: Different mechanism, no overlap — modafinil = wakefulness/DA-norepinephrine; pramiracetam = ACh synthesis/memory. Stack is clean. Pramiracetam can sand off some of modafinil's "narrow tunnel-vision" by adding the verbal/recall lift. Anecdotally common pairing.
• DHA / fish oil (Dylan's V4): Membrane phospholipid substrate for hippocampal neurons; combines well with the HACU/membrane-cycle angle.
• Phosphatidylserine (Dylan's V4): Membrane phospholipid + cortisol modulation; theoretically synergistic with the racetam cholinergic stack.
• L-theanine (Dylan's V4): Smooths the rare irritability some users get on pramiracetam; complementary GABA-tone support.
• Bromantane / Adamax / Semax / Selank (Dylan's V5): Different mechanism (dopaminergic / peptide / neurotrophic) — no overlap, no documented conflicts. Pramiracetam can complement the Russian peptide stack.

Avoid stacking with

• Multiple racetams simultaneously (e.g., daily piracetam + pramiracetam + oxiracetam): Additive choline depletion + diminishing returns. Cross-tolerance and overlap mean the stack delivers less than the sum of doses. Pick one racetam at a time. For Dylan: pramiracetam is the recommended pick if he's running one racetam.
• Phenylpiracetam (daily): Phenylpiracetam tolerates fast and is occasional-only; daily-pramiracetam + daily-phenylpiracetam multiplies the cholinergic load without proportional benefit. PRN co-use is fine if separated by days.
• Strong anticholinergics (diphenhydramine, scopolamine patches): Pharmacological antagonism — defeats the cholinergic mechanism.
• Cholinesterase inhibitors at full dose (donepezil 10 mg, galantamine 24 mg): Theoretical additive cholinergic excess. Low-dose huperzine A (50–200 mcg cycled) is empirically tolerated by many users but is not necessary on top of pramiracetam.

Neutral / safe co-administration

Magnesium (any form), creatine, vitamin D3, vitamin C, NAC, curcumin, beta-alanine, rhodiola, glycine/tryptophan, taurine, apigenin, astaxanthin — Dylan's full V4 daily core is compatible. Caffeine + L-theanine fully compatible (note: caffeine independently affects ACh release, but no documented adverse interaction). Cerebrolysin (V5 cycle) — different mechanism, neutral-to-positive empirical pairing. BPC-157 / TB-500 / GHK-Cu peptides — neutral.

• CYP enzymes: No major CYP interactions documented at therapeutic doses. Not a clinically relevant CYP3A4/2D6/2C9 substrate, inducer, or inhibitor in available data. Limited primary literature — treat as low-interaction-likelihood compound but don't assume zero.
• Hormonal contraceptives: No documented interaction.
• Anticoagulants (warfarin, DOACs): No documented interaction. The NO-synthase-upregulation framing has prompted theoretical caution about platelet effects, but no clinical bleeding signal exists.
• Antidepressants: No documented interaction with SSRIs, SNRIs, MAOIs. The non-monoaminergic mechanism makes serotonin syndrome biologically implausible.
• Anticonvulsants: No documented interaction. Pramiracetam is not pro-convulsant; piracetam-class compounds have been used in adjunctive epilepsy treatment.
• Stimulants (modafinil, amphetamines, methylphenidate): No documented interaction; mechanisms are non-overlapping.
• Alcohol: Not characterized. Empirically tolerated by users. Not relevant for Dylan (zero baseline).
• Anesthesia: Limited data. If undergoing surgery, discontinue 1–2 weeks prior as conservative practice.

• CHT1 / SLC5A7 polymorphisms (the high-affinity choline transporter pramiracetam acts on): No published clinical data on pramiracetam response by SLC5A7 genotype. Theoretically, reduced-function variants might amplify or blunt response — untested.
• APOE genotype: Older Italian dementia studies did not stratify by APOE. APOE4 carriers have known cholinergic deficits and might theoretically respond more — untested.
• CHAT (choline acetyltransferase) variants: Untested. Same theoretical relevance.
• CYP variants: Limited PK pathway, low pharmacogenomic concern.
• For Dylan: Once 23andMe results land (~June 2026), check APOE status. If APOE3/3 (low cholinergic-deficit risk), pramiracetam is a "performance" pick; if any e4 allele, the rationale shifts toward more long-term cholinergic preservation framing.

Sourcing reality 2026: Menarini's 2020 withdrawal of Pramistar effectively ended pharmaceutical-grade availability — current Pramistar stock at CosmicNootropic and similar EU-Russian gray-market vendors is end-of-life inventory. After it clears, all available pramiracetam is research-chem grade from US/EU/China-synthesized vendors with HPLC + COA. COA is mandatory for any purchase; purity claims of 99%+ are routine but vendor-dependent. Cost target: $15–30/month at 300 mg BID PRN-only (Dylan's planned protocol — actually closer to $10/month at PRN frequency).

For Dylan: pick US research-chem vendor with COA (Phenethylamines Lab, Nootropic Source, or Paradigm Peptides capsules). Capsules eliminate scale-error risk for PRN use.

• Baseline (before starting): Subjective cognitive output (verbal fluency, recall, reaction time on a standard task — e.g., dual N-back baseline). Headache frequency. Sleep onset latency. For Dylan: include baseline 23andMe APOE status (lands ~June 2026), bloodwork CBC + LFTs (June window).
• During use: Subjective verbal fluency / cognitive output rating (daily 1–10 on dosing days). Headache occurrence (proxy for choline cofactor adequacy — target zero with adequate citicoline). Sleep onset latency on dosing days vs non-dosing days. For continuous use beyond 4 weeks: rerun CBC + LFTs at 8 weeks and 6 months as conservative surveillance.
• Post-cycle (if cycled): Same subjective ratings 1, 2 weeks after stopping. Watch for 1-week residual benefit (consistent with McLean 1991 finding of post-discontinuation persistence).